Viyash Scientific (512529) Q4 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 25/26 earnings summary
30 May, 2026Executive summary
FY 2026 was transformative, marked by the successful integration of business operations, facilities, and corporate functions, driving record Q4 performance and meaningful merger synergies.
Enhanced execution, operating leverage, and resilience were achieved through disciplined asset utilization, cost controls, and agile pricing amid geopolitical and maritime disruptions.
The company is pursuing both organic and selective inorganic growth, supported by a robust product pipeline, infrastructure investments, and a significantly deleveraged balance sheet.
Audited standalone and consolidated financial results for FY26 were approved, reflecting the impact of a major amalgamation effective April 1, 2025.
The company adopted a new set of Articles of Association and approved a significant employee stock option scheme (ESOP 2026) covering 1,30,98,000 options.
Financial highlights
Q4 FY26 revenue grew 19.1% year-over-year to ₹9,200 Mn; full-year FY26 revenue was ₹34,203.1 Mn, up 13.8% year-over-year.
Q4 gross margin improved to 55.1%; adjusted EBITDA up 63.8% to ₹2,001 Mn, margin at 21.7%. FY26 adjusted EBITDA was ₹7,025 Mn, margin at 20.5%.
Q4 profit before tax swung from a loss of ₹370 Mn to a profit of ₹1,250 Mn; Q4 earnings after tax were ₹664 Mn, up 305.5% YoY.
FY26 net profit after tax was ₹2,246.5 Mn, compared to ₹157.7 Mn in FY25 (restated); consolidated basic EPS for FY26 was ₹4.09.
Net debt reduced to ₹1,661 Mn (0.2x LTM EBITDA) from ₹4,511 Mn (1.0x) in FY25; cash and cash equivalents at year-end stood at ₹2,557.6 Mn.
Outlook and guidance
FY27 priorities include strengthening merger synergies, operational performance, efficient capital allocation, debt reduction, and maximizing cash flow.
Management targets a 15% annual growth rate over the next five years, with EBITDA targets of ₹10,000 Mn in the next 2–3 years.
Gross margins are expected to be maintained at current levels, with potential for slight improvement as the business mix evolves.
Tax rate guidance for FY27 and FY28 is around 26%-27%.
No explicit forward-looking financial guidance was provided.
Latest events from Viyash Scientific
- Merger approval drives record growth, margin expansion, and strong outlook for the combined business.512529
Q2 25/2630 May 2026 - Double-digit growth, margin expansion, and strong cash flow with merger progress and no dividend.512529
Q4 24/2530 May 2026 - Record revenue and EBITDA growth, with merger progress and margin gains despite one-time costs.512529
Q3 24/2529 May 2026 - Q3 FY26 saw strong revenue and margin growth, with merger synergies and new ESOP scheme.512529
Q3 25/2629 May 2026 - Merger forms a global animal health leader with integrated capabilities and immediate margin gains.512529
M&A announcement29 May 2026 - Q2 FY25 saw strong revenue, EBITDA growth, and a transformative merger with Viyash underway.512529
Q2 24/2529 May 2026 - Double-digit revenue and margin growth achieved, with merger synergies and asset gains supporting results.512529
Q1 25/2629 May 2026 - Q1 FY2025 delivered strong revenue and margin growth, driven by Europe, Turkey, and APIs.512529
Q1 24/2529 May 2026